The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 216 of the 312 sources its claims cite were checked for support.
The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy
Open accessAbstract
Inflammatory skin diseases are characterized by complex interactions between immune pathways, epidermal barrier function, and environmental triggers, leading to distinct clinical and histopathological features. This narrative review aims to integrate current knowledge on the cutaneous immune microenvironment across major inflammatory skin diseases, including atopic dermatitis, psoriasis, hidradenitis suppurativa, and vitiligo. A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, focusing on studies published between 2021 and early 2026. The findings highlight disease-specific immune signatures, such as Th2-driven inflammation in atopic dermatitis, IL-23/Th17 axis activation in psoriasis, neutrophil-dominated responses in hidradenitis suppurativa, and cytotoxic T-cell-mediated melanocyte destruction in vitiligo. These molecular pathways are closely reflected in histopathological patterns, emphasizing the link between morphology and immunopathogenesis. Advances in targeted therapies, including biologics and Janus kinase inhibitors, demonstrate the clinical relevance of these pathways and support a transition toward mechanism-based treatment strategies. Dermatopathology is increasingly contributing to precision medicine approaches by supporting correlations between tissue features, immune pathways, and potential therapeutic targets. This review provides a framework for improved disease stratification and for the development of personalized treatment strategies in inflammatory skin diseases.
Overview
CoChat Summary
TL;DR
This is a narrative review arguing that histopathologic patterns in atopic dermatitis, psoriasis, hidradenitis suppurativa, and vitiligo reflect disease-specific immune microenvironments and can help link diagnosis to targeted therapy. It synthesizes recent literature to show how cytokine pathways, barrier defects, and cellular interactions map onto morphology and modern treatments.
Key findings
- Atopic dermatitis is presented as a Th2-dominant disease with acute lesions showing spongiosis, and chronic disease driven by the IL-4/IL-13–JAK–STAT6 axis; the review notes targeted therapies such as dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors.
- Psoriasis is described as being driven primarily by the IL-23/Th17 axis, with classic histology including regular acanthosis, parakeratosis, reduced granular layer, and neutrophilic microabscesses (Munro microabscesses and spongiform pustules of Kogoj); biologics targeting TNF, IL-17, and IL-23 are highlighted as effective.
- Hidradenitis suppurativa is framed as a folliculocentric, neutrophil-rich inflammatory disorder with follicular occlusion, follicular rupture, and epithelialized sinus tracts/tunnels; the review links this to cytokines including IL-1β, TNF-α, IL-17, IL-23, and IL-36, and to adalimumab and secukinumab among current options.
- Vitiligo is described as melanocyte loss driven by cytotoxic T cells and IFN-γ/JAK-STAT signaling; established lesions show marked reduction or complete absence of melanocytes, and topical ruxolitinib plus phototherapy are emphasized as mechanism-based treatments.
Methods
- Narrative review design integrating histopathology, immune mechanisms, and targeted therapy across four inflammatory skin diseases.
- Literature search in PubMed, Scopus, and Web of Science, completed in March 2026, using terms including “cutaneous immune microenvironment,” “dermatopathology,” the four diseases, cytokines, immune pathways, histopathology, targeted therapy, and JAK inhibitors.
- Included English-language original articles, translational studies, clinical studies, and selected review articles published between 2021 and early 2026; no predefined systematic review protocol or formal meta-analysis was used.
Limitations
- The paper states that, because it used a narrative approach rather than a systematic review, it may introduce selection bias and has limited reproducibility.
- The paper states that no formal meta-analysis was performed, so quantitative estimates of histopathologic feature prevalence were not generated.
- The text makes evident that the review is limited to selected diseases and to literature from 2021–early 2026, so its scope is intentionally selective rather than comprehensive (text makes evident).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
100 Valid · 21 Not valid · 12 Not checked · 12 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This mechanistic framework explains the efficacy of biologic therapies targeting TNF, IL-17, and IL-23, which interrupt key nodes in the pathogenic network.”
§ The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy > 5. Psoriasis: Immunopathogenesis and Cytokine Pathways > 5.2. Immune Pathways
What the sources say
- Disputedcites [22] Parigi, 2022, Blockade of IL-23: What is in the Pipeline?, J. Crohns Colitis sourceExperimental — accuracy not yet measured
The Background identifies TNF and IL-23 as therapeutic targets in inflammatory bowel disease, but explicitly contradicts the claimed efficacy of IL-17-targeting biologics in Crohn’s disease. It reports no evidence of efficacy in clinical trials of two such agents and says they may have worsened disease. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [23] Kamata, M., and Tada, Y. (2023). Crosstalk: Keratinocytes and immune cells in psoriasis. Front. Immunol., 14. source
The section on IL-17 and IL-23 inhibition reports that biologics targeting those cytokines alter inflammatory cells and keratinocyte products, and that TNF-α inhibition reduces Th17-induced mediators. The TNF-α and IL-36 section describes an inflammatory loop involving TNF-α and IL-23. Together, these passages support the claim that the therapies act on key parts of the pathogenic network. (LLM, conf=0.88)
- Partly supportedcites [24] Huang, 2021, HLA-Cw1 and Psoriasis, Am. J. Clin. Dermatol. sourceExperimental — accuracy not yet measured
The “HLA-Cw1 and Clinical Presentations of Psoriasis” section (page unavailable) reports responses to anti-IL-17 and anti-IL-23 drugs in HLA-Cw6-positive patients, but says anti-TNF agents showed less efficacy in that group. The paper does not connect these treatment responses to interruption of TNF, IL-17, and IL-23 nodes in a pathogenic network, so it supports the treatment-response point only in a narrower form. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These features are not only diagnostically useful but also reflect disease-specific immune mechanisms that increasingly inform therapeutic targeting across inflammatory dermatoses [1,2,3,4,5].”
§ The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy > 1. Introduction
What the sources say
- Partly supportedcites [1] Andrzejczak, K., Sternak, A., Witkowski, W., and Ponikowska, M. (2025). Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?. Cells, 14. sourceExperimental — accuracy not yet measured
Section 5.1 links disease-specific immune pathways to targeted treatment, describing Th2-directed therapy for atopic dermatitis and IL-17-directed therapy for psoriasis and hidradenitis suppurativa. The passages do not establish that diagnostic histopathological features reflect those mechanisms or inform treatment selection. Page numbers were not available in our copy. (LLM, conf=0.85)
- Partly supportedcites [2] Czarnowicki, 2024, CLA+ memory T cells in atopic dermatitis, Allergy sourceExperimental — accuracy not yet measured
Section 2, “CLA+ T Cells in AD” (page not available), links immune pathways and cells in atopic-dermatitis lesions to targeted therapies, clinical features, and biomarkers. It does not establish that diagnostic histopathological features reflect those mechanisms or support the generalization across inflammatory dermatoses. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] Karpathiou, 2021, STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology, Pathol. Res. Pract. source
- Not checked — no full text of the sourcecites [4] You, 2025, Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier, Clin. Rev. Allergy Immunol. source
- Partly supportedcites [5] Kashyap, 2022, Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling, Semin. Cell Dev. Biol. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) links histological inflammation in hidradenitis suppurativa (HS) to cytokine activity and describes responses to targeted treatments. It does not establish that histopathological features are diagnostically useful across inflammatory dermatoses; it says exact diagnosis of HS remains difficult without better mechanistic understanding. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to circulating immune cells, tissue-resident memory T cells contribute to the persistence and recurrence of inflammation, emphasizing the importance of local immune regulation.”
§ The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy > 3. The Cutaneous Immune Microenvironment > 3.1. Cellular Components
What the sources say
- Partly supportedcites [1] Andrzejczak, K., Sternak, A., Witkowski, W., and Ponikowska, M. (2025). Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?. Cells, 14. sourceExperimental — accuracy not yet measured
Section 2.1 (page unavailable) says altered T-cell homeostasis perpetuates chronic inflammation and mentions an increased proportion of memory T-cell subsets. It does not identify tissue-resident memory T cells or link them to the recurrence of inflammation; searches for “resident memory” and “recurrence of inflammation” found no such passage. (LLM, conf=0.78)
- Could not verifycites [5] Kashyap, 2022, Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling, Semin. Cell Dev. Biol. sourceExperimental — accuracy not yet measured
The ‘Plasma cells, B cells and T cells’ section describes T-cell infiltration in HS skin but does not identify tissue-resident memory T cells or link them to persistent or recurrent inflammation. The ‘Macrophages and DCs’ section discusses recurrence in connection with occult inflammation and plasmacytoid dendritic cells. Searches for ‘tissue-resident memory T cells,’ ‘resident memory,’ and ‘memory T cells’ found no passage supporting the attributed role; page numbers were unavailable. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cutaneous immune microenvironment consists of a highly coordinated network of cells, including keratinocytes, dendritic cells, macrophages, and T lymphocytes.”
§ The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy > 3. The Cutaneous Immune Microenvironment > 3.1. Cellular Components
What the sources say
- Supportedcites [1] Andrzejczak, K., Sternak, A., Witkowski, W., and Ponikowska, M. (2025). Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?. Cells, 14. source
Section 4.2 describes Th2 lymphocytes, macrophages, dendritic cells, and keratinocytes as participants in the IL-31 inflammatory pathway. Section 4.1 also describes interactions between dendritic cells and macrophages and Th17 lymphocytes in activated skin. Together, these passages support the description of an interacting cutaneous cell network; page numbers were not available in our copy. (LLM, conf=0.88)
- Supportedcites [5] Kashyap, 2022, Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling, Semin. Cell Dev. Biol. source
The 'Dysregulated immune system and HS' sections on keratinocytes and on macrophages and DCs describe these cells' roles in skin inflammation, including dendritic-cell interactions with T cells. The 'ECM and HS' section also describes interactions among skin cells and immune cells. Together, these passages support the broad characterization of a coordinated cutaneous immune network; page numbers are unavailable in our copy. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In the dermis, a superficial perivascular inflammatory infiltrate composed mainly of lymphocytes is typically observed.”
§ The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy > 4. Atopic Dermatitis: Th2-Dominated Microenvironment > 4.1. Histopathology
What the sources say
- Not checked — no full text of the sourcecites [4] You, 2025, Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier, Clin. Rev. Allergy Immunol. source
- Could not verifycites [5] Kashyap, 2022, Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling, Semin. Cell Dev. Biol. sourceExperimental — accuracy not yet measured
The Introduction describes lymphocytic inflammation around hair follicles in hidradenitis suppurativa, not a superficial perivascular infiltrate in atopic dermatitis. Searches for atopic dermatitis and perivascular lymphocytic infiltration found no passage in our copy addressing the claimed finding. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
73 more claims · 61 with their cited sources checked
Create a free account to see all 145 claims and every source verdict.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 8
Citations
Cites
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501 · cited 2×
“Collectively, these mechanisms establish a self-amplifying loop in which barrier dysfunction and type 2 immune responses reciprocally reinforce each other, underlying both disease initiation and chronicity in atopic dermatitis [9,10].”
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346 · cited 4×
“The other characteristics mentioned are not always seen [20,21].”
InfluentialUpdate on the Pathogenesis and Therapy of Atopic Dermatitis
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08880-3 · Cited by 277 · cited 2×
“In parallel, neuroimmune mechanisms have emerged as important modulators of cytokine signaling, linking neuronal pathways to immune activation and contributing to disease symptoms such as pruritus [2,6].”
Angiogenesis in Chronic Inflammatory Skin Disorders
Lee, H. J., Hong, Y. J., & Kim, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112035 · Cited by 211 · cited 3×
“Increasing real-world evidence also supports the durable efficacy and favorable long-term disease control achieved with selective IL-23 inhibitors [27,28].”
Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review
Qi, F., Liu, F., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790125 · Cited by 203 · cited 1×
“Non-immune mechanisms also play a role, including defective melanocyte adhesion (melanocytorrhagy), endoplasmic reticulum stress, and altered cellular metabolism, all of which increase melanocyte susceptibility to immune-mediated destruction [50–52].”
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192 · cited 4×
“The other characteristics mentioned are not always seen [20,21].”
InfluentialBissonnette, R., Stein Gold, L., Rubenstein, D. S., Tallman, A. M., & Armstrong, A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.10.085 · Cited by 181 · cited 1×
“For example, aryl hydrocarbon receptor modulators such as tapinarof influence keratinocyte differentiation, oxidative stress, and inflammatory gene expression, representing a non-immunosuppressive approach that targets both epithelial and immune components of the disease [33,34].”
Current Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163
Peripheral itch sensitization in atopic dermatitis
Tominaga, M., & Takamori, K. (2022) · Allergology International · doi:10.1016/j.alit.2022.04.003 · Cited by 160 · cited 2×
“Collectively, these mechanisms establish a self-amplifying loop in which barrier dysfunction and type 2 immune responses reciprocally reinforce each other, underlying both disease initiation and chronicity in atopic dermatitis [9,10].”
Hidradenitis Suppurativa: Where We Are and Where We Are Going
Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., & Fabbrocini, G. (2021) · Cells · doi:10.3390/cells10082094 · Cited by 135 · cited 4×
“Progression leads to follicular rupture, with release of keratin, hair shaft fragments, and microbial products into the dermis [38,39].”
Influential
Cited by
Ballard, J. M., Chiguru, R., Deeb, M. B., Swatsburg, R. B., Lau, A. Y., Davis, G. H., Demiri, M., Keller, J. T., Nourachi, B., Shihadeh, T. A. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177689
Metadata
- Authors
- Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S.
- Affiliations
- Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș (RO)
- Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania
- Venue
- Dermatopathology
- Publisher
- MDPI AG
- Published
- 2026-05-10
- Volume
- 13
- Issue
- 2
- Pages
- 22
- ISSN
- 2296-3529 (ISSN-L)
- PMC
- PMC13214635
- OpenAlex
- W7160825141
- Cited by
- 1
- References
- 54
- Citations by year
- 2026: 1
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Dermatopathology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- inflammatory skin diseases, atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, IL-23/Th17 axis, neutrophilic inflammation, cytotoxic T lymphocytes, melanocyte destruction, biologic therapy, JAK inhibitors, precision medicine, disease stratification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy. https://app.cochat.ai/papers/10.3390/dermatopathology13020022
- The paper
- Tinca, A. C., Cozac-Szoke, A. R., & Cotoi, O. S. (2026). The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy. Dermatopathology. https://doi.org/10.3390/dermatopathology13020022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.